219 related articles for article (PubMed ID: 15308883)
1. Clinical experience with angiotensin receptor blockers with particular reference to valsartan.
Chrysant SG; Chrysant GS
J Clin Hypertens (Greenwich); 2004 Aug; 6(8):445-51. PubMed ID: 15308883
[TBL] [Abstract][Full Text] [Related]
2. The antihypertensive effectiveness and safety of dual RAAS blockade with aliskiren and valsartan.
Chrysant SG
Drugs Today (Barc); 2010 Mar; 46(3):151-62. PubMed ID: 20467589
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin receptor blocker added to previous antihypertensive agents on arteries of diabetic hypertensive patients.
Savoia C; Touyz RM; Endemann DH; Pu Q; Ko EA; De Ciuceis C; Schiffrin EL
Hypertension; 2006 Aug; 48(2):271-7. PubMed ID: 16785331
[TBL] [Abstract][Full Text] [Related]
4. Role of valsartan and other angiotensin receptor blocking agents in the management of cardiovascular disease.
Martin J; Krum H
Pharmacol Res; 2002 Sep; 46(3):203-12. PubMed ID: 12220962
[TBL] [Abstract][Full Text] [Related]
5. The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design.
Mann J; Julius S
Blood Press; 1998 May; 7(3):176-83. PubMed ID: 9758088
[TBL] [Abstract][Full Text] [Related]
6. Aliskiren/valsartan combination for the treatment of cardiovascular and renal diseases.
Yarows SA
Expert Rev Cardiovasc Ther; 2010 Jan; 8(1):19-33. PubMed ID: 20030022
[TBL] [Abstract][Full Text] [Related]
7. Preventing cardiovascular events with angiotensin II receptor blockers: a closer look at telmisartan and valsartan.
Volpe M
Expert Rev Cardiovasc Ther; 2012 Aug; 10(8):1061-72. PubMed ID: 23030295
[TBL] [Abstract][Full Text] [Related]
8. JIKEI HEART Study--a morbi-mortality and remodeling study with valsartan in Japanese patients with hypertension and cardiovascular disease.
Mochizuki S; Shimizu M; Taniguchi I; Kanae K; Yoshida S; Tajima N; Dahlöf B;
Cardiovasc Drugs Ther; 2004 Jul; 18(4):305-9. PubMed ID: 15367828
[TBL] [Abstract][Full Text] [Related]
9. Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
Grothusen A; Divchev D; Luchtefeld M; Schieffer B
Minerva Cardioangiol; 2009 Dec; 57(6):773-85. PubMed ID: 19942847
[TBL] [Abstract][Full Text] [Related]
10. Valsartan in the treatment of heart failure or left ventricular dysfunction after myocardial infarction.
Bissessor N; White H
Vasc Health Risk Manag; 2007; 3(4):425-30. PubMed ID: 17969373
[TBL] [Abstract][Full Text] [Related]
11. [Angiotensin II receptor blockers: current status and future prospects].
Corvol P; Plouin PF
Drugs; 2002; 62 Spec No 1():53-64. PubMed ID: 12036389
[TBL] [Abstract][Full Text] [Related]
12. Role of combination therapy in the treatment of hypertension: focus on valsartan plus amlodipine.
Ferri C; Croce G; Desideri G
Adv Ther; 2008 Apr; 25(4):300-20. PubMed ID: 18449492
[TBL] [Abstract][Full Text] [Related]
13. Fixed combination therapy of hypertension: focus on valsartan/hydrochlorothiazide combination (Diovan/HCT).
Chrysant SG
Expert Rev Cardiovasc Ther; 2003 Sep; 1(3):335-43. PubMed ID: 15030262
[TBL] [Abstract][Full Text] [Related]
14. Valsartan: more than a decade of experience.
Black HR; Bailey J; Zappe D; Samuel R
Drugs; 2009; 69(17):2393-414. PubMed ID: 19911855
[TBL] [Abstract][Full Text] [Related]
15. Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial.
Solomon SD; Janardhanan R; Verma A; Bourgoun M; Daley WL; Purkayastha D; Lacourcière Y; Hippler SE; Fields H; Naqvi TZ; Mulvagh SL; Arnold JM; Thomas JD; Zile MR; Aurigemma GP;
Lancet; 2007 Jun; 369(9579):2079-87. PubMed ID: 17586303
[TBL] [Abstract][Full Text] [Related]
16. A drug safety evaluation of valsartan.
Fogari R; Zoppi A
Expert Opin Drug Saf; 2011 Mar; 10(2):295-303. PubMed ID: 21142805
[TBL] [Abstract][Full Text] [Related]
17. Effects of valsartan, an angiotensin II receptor blocker, on coronary atherosclerosis in patients with acute myocardial infarction who receive an angiotensin-converting enzyme inhibitor.
Yano H; Hibi K; Nozawa N; Ozaki H; Kusama I; Ebina T; Kosuge M; Tsukahara K; Okuda J; Morita S; Umemura S; Kimura K
Circ J; 2012; 76(6):1442-51. PubMed ID: 22473458
[TBL] [Abstract][Full Text] [Related]
18. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy.
Galle J; Schwedhelm E; Pinnetti S; Böger RH; Wanner C;
Nephrol Dial Transplant; 2008 Oct; 23(10):3174-83. PubMed ID: 18450829
[TBL] [Abstract][Full Text] [Related]
19. Hypertension therapy and cardiovascular protection. Effects of angiotensin II receptor block with Valsartan.
Sestito A
Eur Rev Med Pharmacol Sci; 2011 Nov; 15(11):1247-55. PubMed ID: 22195356
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic potential of angiotensin receptor blockers in hypertension.
Cheung BM
Expert Opin Investig Drugs; 2006 Jun; 15(6):625-35. PubMed ID: 16732715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]